Serum Institute of India acquires 20% stake in IntegriMedical
The largest vaccine manufacturer in the world, Serum Institute of India (SII), purchased a 20% share in IntegriMedical, a US-based company, in order to further the development of needle-free injection system technology.
The deal’s financial specifics were kept
under wraps.
In a statement released on Friday,
Pune-based SII said that the collaboration with IntegriMedical is in line with
both company’s goals of “Health for All” and “Transforming Healthcare Globally”
through the provision of patient comfort, assurance of improved patient
compliance, a decrease in needle-stick injuries, and an improvement in the
effectiveness of liquid medication through needle-free dispersion.
Comments
Post a Comment